Trial Profile

Treatment Options for Protease Inhibitor-exposed Children.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abacavir (Primary) ; Efavirenz (Primary) ; Lopinavir/ritonavir; Stavudine
Indications HIV infections
Focus Therapeutic Use
Acronyms NEVEREST-3; NEVEREST-III

Most Recent Events

17 Apr 2017 Results assessing long term outcomes of the trial, published in the Clinical Infectious Diseases
16 Feb 2017 Results of cost effectiveness of preemptive switch to efevirenz presented at the 24th Conference on Retroviruses and Opportunistic Infections
03 Nov 2015 Results (n=298) published in the JAMA: the Journal of the American Medical Association

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com